CLOSING THE GENOTYPE-PHENOTYPE LOOP
In this issue of Circulation, Barefield and colleagues present state-of-the-art strategies to assess the causality of newly identified variants in potential cardiovascular disease genes. 12 The team identified a premature stop codon (R255X) in the myosin-binding protein Hlike (MYBPHL) gene among 3 relatives with dilated cardiomyopathy (DCM), prominent atrioventricular conduction disease, and atrial arrhythmias.
Although this premature stop codon occurs in a gene that is structurally related to myosin-binding protein C (MYBPC3), a definitive cardiomyopathy gene, there are several features of the R255X variant in MYBPHL that illuminate the complexity of establishing pathogenicity and genotype-phenotype correlations. The R255X variant occurs at significant frequency in sequencing databases from generally healthy individuals, suggesting that it is not under heavy negative genetic selection, as occurs when variants cause early-onset morbid conditions. Recognizing that similar variants in MYBPC3 produce a range of phenotypes (hypertrophic or dilated cardiomyopathies or predisposition to adverse ventricular remodeling), the authors analyzed additional patients with DCM but identified only one with the MYBPHL R255X variant. Next, they turned to experimental approaches, documenting high atrial but low ventricular expression of MYBPHL with an unusual punctate subcellular localization, suggesting a novel role for this myofilament protein. Harnessing patient-derived induced pluripotent stem cells to generate cardiomyocytes, they established that the R255X allele fails to make stable MYBPHL protein. Finally, they extensively characterized mice in which the MYBPHL gene was deleted and demonstrated contractile defects in both heterozygotes and homozygote mutant mice. Although MYBPHL null mice had atrial arrhythmias that are similar to those observed in the R255X patients, there were no baseline atrioventricular conduction abnormalities, and only with isoprenaline infusion was there ventricular conduction delay. Together these data buttress MYBPHL as a candidate DCM/arrhythmia gene, but as is clearly (and laudably) stated by this thoughtful research team, there remains the real possibility for a chance association of the MYB-PHL R255X variant and DCM in this particular family.
What would we need to know to be able to definitively attribute causality to a variant in the context of the nonspecific phenotypes currently used in clinical and preclinical medicine? Despite extensive experimental investigation and while appreciating that some of the discordances reflect species or allelic differences, the totality of data still limits the certainty with which it is possible to attribute causality. We speculate that more human data could provide additional and potentially powerful evidence. It would be vital to know how many deleterious coding variants in other genes were identified in the affected individuals in this family. It would also be of interest to know if there were noncoding abnormalities in genes already implicated in DCM with conduction disease. A specific molecular and functional defect shared between patients and experimental models would also aid in understanding the likelihood that this gene defect is truly the cause of the morbid disease in this family. Ultimately, measuring identical and specific phenotypes in humans and model systems to complement the tight genetic orthologies that we already can identify will accelerate a probabilistic understanding of causality in individual patients. Such a probabilistic understanding of mechanism will herald the arrival of precision diagnosis and the potential this brings to improve disease management.
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